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Abstract
Several recent meta-analyses have shown that the use of SDD can reduce the occurrence
of nosocomial pneumonia among ventilated patients in the intensive care unit (ICU) setting.
However, the use of SDD has also been demonstrated to increase subsequent patient
colonization and infection with antibiotic-resistant bacteria, particularly Gram-positive cocci.
Therefore, the routine use of SDD cannot be advocated at the present time. The mortality
benefit of SDD appears to occur in surgical/trauma patients, and to be associated primarily
with the administration of parenteral antibiotics. This is already an accepted practice in most
patients during the perioperative period (eg prophylactic parenteral antibiotics for 24 h).
Prolonged decontamination of the aerodigestive tract with topical antimicrobials does not
appear to influence outcome, and should not be routinely employed.
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Introduction
The most important factor influencing the emergence of
antibiotic-resistant bacterial infections is the extensive use
of antimicrobial agents both within hospitals and in the
community. Recently, Levy [1] formulated five underlying
principles of antimicrobial resistance that highlight the
importance of antibiotic use as a risk factor. First, given
sufficient time and drug use, antibiotic resistance will
emerge. Second, antibiotic resistance is progressive,
evolving from low levels through intermediate to high
levels. Third, organisms that are resistant to one drug are
likely to become resistant to other antibiotics. Fourth, once
resistance appears, it is likely to decline slowly, if at all.
Finally, the use of antibiotics by any one person affects
others in the extended and in the immediate environment.
These principles apply to all antibiotic administration,
including the use of SDD. Therefore, the clinical benefits
of SDD must be balanced against the potential for the
greater emergence of antibiotic-resistant infections as a
result of its use.
ICUs, along with other specialty areas within hospitals (eg
organ transplant wards, oncology units), frequently have
high levels of antimicrobial usage among patients who areCritical Care    Vol 4 No 6 Kollef
maintained in close proximity. This type of environment
may explain the high levels of antimicrobial resistance that
are observed within such areas of the hospital.
A recent multicenter European survey [2] examined a total
of 9166 Gram-negative bacterial strains from 7308
patients in ICUs from 118 hospitals. The most frequently
isolated organisms were Enterobacteriaceae (59%) fol-
lowed by Pseudomonas aeruginosa (24%), with the main
sources being respiratory tract (42%), urine (26%), blood
(14%), abdomen (11%), and skin and soft tissue (7%).
Decreased antibiotic susceptibility was most common for
P aeruginosa, Acinetobacter spp, and Enterobacter spp.
Resistance to ceftazidime was greater than 70% in some
countries for Acinetobacter spp, whereas P aeruginosa
was associated with the highest overall incidence of resis-
tance in all the countries surveyed (37% resistant to
ciprofloxacin in Portugal, 24% resistant to imipenem in
France). Similar findings were demonstrated in the USA
[3], where 33 869 nonduplicate Gram-negative isolates
were examined from 396 ICUs from 45 states. Resistance
to third-generation cephalosporins was found to be an
emerging problem, with increasing resistance to cef-
tazidime between 1990 and 1993 for Klebsiella pneumo-
niae (3.6–14.4%;  P < 0.01) and Enterobacter spp
(30.8–38.3%;  P = 0.0004). Additionally, ceftazidime resis-
tant Gram-negative bacteria were also frequently resistant
to aminoglycosides and ciprofloxacin. These data highlight
the presence of important antibiotic resistance among
clinically important bacterial species within ICUs in Europe
and the USA.
A number of investigators have demonstrated a close
association between the use of antibiotics and the emer-
gence of antibiotic resistance in both Gram-negative and
Gram-positive bacteria [4–8]. The recent experience with
antibiotic cycling or scheduled antibiotic class changes
also demonstrates how rapidly antibiotic-resistant bacteria
can emerge within the hospital setting as antibiotic use
patterns change [9–11]. Trouillet et al [12] examined 135
consecutive episodes of ventilator-associated pneumonia,
of which 77 (57%) were caused by potentially antibiotic-
resistant bacteria (methicillin-resistant Staphylococcus
aureus, P aeruginosa, Acinetobacter baumannii, and
Stenotrophomonas maltophilia). According to logistic
regression analysis, duration of mechanical ventilation for
7 days or more, prior antibiotic use, and prior use of
broad-spectrum antibiotics (third-generation cephalo-
sporins, fluoroquinolones, and/or imipenem) were associ-
ated with the development of ventilator-associated
pneumonia due to antibiotic-resistant pathogens. This
investigation confirmed the importance of previous antibi-
otic exposure as a risk factor for the development of noso-
comial infections due to antibiotic-resistant bacteria
[13–15]. Additionally, the identification of specific risk
factors for the occurrence of antibiotic-resistant infections,
such as prior antimicrobial exposure, provides guidance
for the development of potential interventions that are
aimed at reducing these rates of infection and at providing
better antimicrobial treatment when they occur [16,17].
In addition to prior antibiotic exposure, other risk factors
have been associated with the emergence of antibiotic-
resistant infections. Prolonged duration of stay in the hos-
pital appears to predispose to infection with
antibiotic-resistant bacteria [12]. This may be partly due to
the greater likelihood of becoming colonized with such
bacteria, from either horizontal nosocomial transmission or
endogenous emergence of resistance, the longer a patient
remains in hospital. Similarly, the presence of invasive
devices such as endotracheal tubes, intravascular
catheters, and urinary catheters also predisposes to infec-
tion with antibiotic-resistant and antibiotic-sensitive bacte-
ria [18]. Patients who are treated with SDD typically
require intensive care. Therefore, the risk factors noted
above that predispose to the emergence of antibiotic
resistance should be applicable to patients receiving
SDD. Unfortunately, large, long-term investigations of the
use of SDD, examining the influence of SDD on antibiotic
susceptibility patterns for clinically important micro-organ-
isms in the ICU setting, have not been performed.
Recent meta-analyses of selective digestive
decontamination
Two recent meta-analyses have been conducted that
review the use of SDD. The first is a European review
published in the British Medical Journal [19]. That review
concluded that 15 years of clinical research suggests
that antibiotic prophylaxis with a combination of topical
and systemic antibiotics can reduce respiratory tract
infections and overall mortality in critically ill patients. The
authors stated that “This effect is significant and worth-
while, and it should be considered when practice guide-
lines are defined.” However, that study observed a
reduction in mortality only when the use of topical and
systemic antibiotic prophylaxis was compared with no
use of prophylaxis (16 studies reviewed). There was no
difference in mortality when topical and systemic anti-
biotic prophylaxis was compared with systemic antibiotic
prophylaxis alone (seven studies) and when topical anti-
biotic prophylaxis was compared with no antibiotic pro-
phylaxis (11 studies). These findings suggest that it is the
administration of systemic antibiotic prophylaxis, and not
the administration of topical antibiotic prophylaxis, that is
responsible for the observed reduction in mortality.
Another important element of this analysis is that the
majority of patients evaluated who had a survival advan-
tage were surgical and trauma patients (>70%). Trauma
and surgical patients have previously been shown to
derive benefits from the use of systemic antibiotic prophy-
laxis, including reduced rates of nosocomial infection and
improved hospital survival [20,21].http://ccforum.com/content/4/6/327
The second, more recent meta-analysis was conducted by
Nathens and Marshall from Canada [22]. Those investiga-
tors found that there was no survival advantage with SDD
in 10 studies in which postoperative and trauma patients
constituted no more than 25% of the overall study popula-
tion. A survival advantage was found in 11 studies in
which postoperative and trauma patients constituted more
than 75% of the study population. That meta-analysis also
showed that the survival advantage was greatest in
studies in which both topical and systemic antibiotic pro-
phylaxes were used. The main conclusion of the investiga-
tion was that “SDD notably reduces mortality in critically ill
surgical patients, while critically ill medical patients derive
no such benefit. These data suggest that the use of SDD
should be limited to those populations in whom rates of
nosocomial infection are high and in whom infection con-
tributes notably to adverse outcomes.”
Interestingly, both of those analyses reported similar
results. A common flaw of those studies is a lack of a clear
definition for SDD. It should be viewed as the use of
antimicrobial agents to reduce oropharyngeal and gas-
trointestinal colonization by pathogenic micro-organisms,
primarily Gram-negative bacilli and Candida spp. Nathens
and Marshall [22] defined SDD as being made up of two
components. The first component consists of topical, non-
absorbed antimicrobials, including polymyxin E, tobra-
mycin, and amphotericin B, a combination that is active
against aerobic Gram-negative bacteria and fungi. The
second component is intravenous cefotaxime sodium, or
an equivalent parenteral antibiotic, which is generally
administered for 4 days after the initiation of SDD.
However, the European meta-analysis demonstrated that
there is considerable variation in how SDD is employed
(topical antibiotics alone, topical and systemic antibiotics,
variations in duration of antibiotic administration, variability
in individual antimicrobials employed). Additionally, an
important objective of the SDD strategy is to preserve the
normal anaerobic flora within the intestinal lumen in order
to prevent overgrowth with pathogenic organisms. Unfor-
tunately, this has not been demonstrated to occur. The
available clinical data suggest that SDD alters the host’s
bacterial flora, predisposing to the emergence of coloniza-
tion and infection with antibiotic-resistant pathogens;
these data are reviewed below.
Selective digestive decontamination and
antibiotic resistance
In one of the largest trials of SDD, Gastinne et al [23]
found that pneumonia due to staphylococci was more
common among SDD-treated patients. The emergence of
pneumonia due to Gram-positive bacteria in association
with the use of SDD has also been reported by other
investigators [24]. Hammond and Potgieter [25] found a
statistically significant increase in the occurrence rate of
infections caused by Acinetobacter spp in the year after
beginning a trial of SDD in their ICU compared with the
year preceding the trial (8.9% versus 5.2%; P = 0.05).
Additionally, Acinetobacter spp became the most common
pathogens to colonize patients in their unit during this time
period, although this could not be specifically linked to the
use of SDD. Sanchez-Garcia et al [26] demonstrated
reductions in the overall occurrence of nosocomial pneu-
monia with the use of SDD. However, the level of carriage
of methicillin-resistant S aureus, coagulase-negative
staphylococci, and enterococci was significantly higher in
the SDD-treated patients. In a large study performed in
Belgium [27], significantly more bacteremias due to Gram-
positive bacteria were observed among SDD-treated
patients. Increased antimicrobial resistance was also
detected among the SDD-treated patients, including
tobramycin-resistant Enterobacteriaceae, ofloxacin-resis-
tant nonfermenters, ofloxacin-resistant Enterobacteri-
aceae, and methicillin-resistant S aureus. Finally, patient
colonization with pathogenic bacteria including Acineto-
bacter spp, in areas such as the skin and pharynx, which
may not be decontaminated by SDD, cast doubt on the
overall value of SDD as a useful clinical practice [28].
As a result of this controversy, the use of SDD has not
been commonplace in the USA. Similarly, clinical use of
SDD has not gained a strong foothold in Europe, the con-
tinent in which it has been most extensively investigated
[29]. In large part, it appears that fears over emerging
antimicrobial resistance have limited the general use of
SDD in Europe. A recent European consensus conference
[29] surveyed 279 ICU physicians on their use of SDD. It
was used to treat all ventilated patients by 18%, 50%
‘never’ employed SDD, and 32% used SDD for selected
diagnoses and during epidemic outbreaks of infection.
Interestingly, among the respondents surveyed 2 years
earlier about their practices, 92% had not changed their
practices. Cefotaxime or a second-generation cephalo-
sporin was found to be the most common antibiotic
employed (73%) for systemic administration, along with
topical antibiotic prophylaxis. A concerning finding of this
survey was the absence of any influence of rising anti-
microbial resistance rates in Europe on clinical practices
[2]. Most respondents using SDD employed the same
antibiotics during the years between the survey, and did
not have epidemiologic data concerning predominant
microbial pathogens and their antibiotic susceptibilities to
help guide the use of SDD in their ICUs.
Implications of increasing bacterial antibiotic
resistance
In general, infections with antibiotic-resistant bacteria are
associated with greater hospital mortality and longer dura-
tion of hospital stay [30]. Colonization and infection with
antibiotic-resistant bacteria increase the likelihood that
patients will receive inadequate antimicrobial therapy (ie
antimicrobial therapy for which the identified causativemicro-organisms are resistant). Several investigations have
demonstrated a strong association between the adminis-
tration of inadequate antibiotic treatment and increased
hospital mortality rates for patients with ventilator-associ-
ated pneumonia [31–33]. Those studies independently
demonstrated that patients who receive inadequate
empiric antimicrobial treatment, initiated before obtaining
the results of cultures from respiratory secretions, blood,
and pleural fluid, had greater hospital mortality rates than
did patients who received empiric antimicrobial regimens
that provided full coverage of all identified bacterial
pathogens. More importantly, for patients receiving initially
inadequate treatment, it appears that changing antimicro-
bial therapy on the basis of available culture results may
not reduce the excess risk of hospital mortality associated
with inadequate antibiotic treatment [32]. Therefore, the
timing of the administration of adequate antimicrobial
therapy is an important determinant of outcome for
patients with ventilator-associated pneumonia.
Most inadequate antimicrobial treatment of nosocomial
infections appears to be due to infection with antibiotic-
resistant Gram-negative and antibiotic-resistant Gram-
positive bacteria [17]. Although inadequate antibiotic
therapy may explain, in part, the greater mortality rates
associated with antibiotic-resistant bacterial infections,
other factors may also contribute to this excess mortality.
Gram-positive bacterial pathogens such as S aureus can
express a number of virulence factors that potentially con-
tribute to the high rates of mortality associated with infec-
tions with these pathogens [34]. The presence of
methicillin resistance in S aureus appears to enhance
further its virulence and likelihood of infection-related mor-
tality [35]. However, not all investigators have demon-
strated greater mortality rates with infections due to
methicillin-resistant S aureus compared with methicillin-
sensitive S aureus [36]. Some antibiotic-resistant Gram-
negative bacteria are also associated with increased
virulence factors as compared with antibiotic-susceptible
pathogens [37]. This may explain some of the excess
attributable mortality observed in clinical studies that
examined infections due to antibiotic-resistant Gram-nega-
tive bacteria [38].
Nosocomial blood-stream infections are among the most
serious infections acquired by hospitalized patients. The
coexistence of a pathogen population with an ever-
increasing resistance to many antibiotics and a patient
population that is characterized by increasingly complex
clinical problems has contributed to an increase in blood-
stream infections, particularly due to antibiotic-resistant
Gram-positive bacteria [39]. Antibiotic resistance appears
to have contributed to increasing administration of inade-
quate antimicrobial therapy for nosocomial blood-stream
infections, which is associated with greater hospital mor-
tality rates [40,41]. The problem of antibiotic-resistant
bacteremia appears to be increasing both in the hospital
setting and in the community [42]. Given the current trend
of greater severity of illness for hospitalized patients, it can
be expected that infections due to antibiotic-resistant bac-
terial strains will be associated with greater morbidity and
mortality, particularly when inadequate empiric antimicro-
bial therapy is administered [17].
In addition to higher patient mortality rates, antibiotic-resis-
tant bacterial infections are associated with prolonged
hospitalization and increased health care costs relative to
antibiotic-sensitive bacterial infections [43]. Recently, a
study from Beth Israel Deaconess Medical Center [44]
examined 489 inpatients with positive clinical cultures for
P aeruginosa. The emergence of antibiotic resistance in
infections with P aeruginosa was independently associ-
ated with greater hospital mortality and longer duration of
hospital stay. Those investigators estimated that the emer-
gence of antibiotic resistance increased hospital charges
by US$11981. Other authors have also reported
increased medical care costs associated with antibiotic-
resistant infections [45]. The overall national costs of
antimicrobial resistance in the USA have been estimated
to be between US$100 million and US$30 billion annually
for the control and treatment of infections caused by
antibiotic-resistant bacteria [43,46]. The increased costs
of infection due to antibiotic-resistant bacteria have been
attributed to prolonged hospitalizations and greater anti-
biotic costs [47]. Additionally, the emergence of antibiotic
resistance results in the need to develop new antimicro-
bial agents [48,49]. The costs required for the develop-
ment of new antimicrobial agents, including the necessary
clinical research to demonstrate their effectiveness and
safety, has also increased during the past decade [50].
This possibly explains, in part, the relatively slow develop-
ment of new antibiotics.
Conclusion
Antibiotic resistance has become a major concern for both
community-acquired and nosocomial infections. The
development and use of SDD has occurred during the
recent explosion in infections due to antibiotic-resistant
micro-organisms. Unfortunately, the overall impact of SDD
on the development of antibiotic resistance cannot be fully
determined on the basis of the existing medical literature.
However, several factors suggest that the use of SDD
should be carefully monitored as a potential stimulus for
further antimicrobial resistance [1,51]. First, low-level
antimicrobial resistance usually precedes high-level resis-
tance. Second, antibiotic resistance may require pro-
longed periods before clinical consequences are
observed. Third, resistance often starts with selection of
microbes from the normal flora that possess plasmids with
transferable resistances. This has resulted in important
outbreaks of nosocomial infections due to Escherichia coli
and Klebsiella pneumoniae, which possess plasmids for
Critical Care    Vol 4 No 6 Kolleftype-1 b-lactamase production due to selective pressures
from the use of cephalosporins and aminoglycosides.
Finally, we have experienced difficulty in predicting the
emergence of resistance. The recent experience with
Streptococcus pneumoniae resistant to fluoroquinolones
and S aureus with intermediate resistance to vancomycin
highlight this fact. On the basis of this experience, and the
likelihood that antimicrobial resistance will continue to be
a major problem for the future, the routine or indiscriminate
clinical use of SDD cannot be recommended.
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